Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks brain and energy side effects of prostate cancer meds

NCT ID NCT07181122

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and 6 months using simple questionnaires. The goal is to see how these treatments affect daily life and mental function in the real world.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Androgen receptor pathway inhibitors (abiraterone, apalutamide, enzalutamide, darolutamide)
What this could lead to
If successful, this study could help doctors understand how these drugs affect thinking, energy, and mood, leading to better support for patients.
What could go wrong
This is an observational study, not a treatment trial. It only measures outcomes without testing a new therapy, so it won't directly improve treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male patients aged 18 years and older with histologically or cytologically confirmed metastatic hormone-sensitive prostate cancer, initiating androgen deprivation therapy plus an androgen receptor pathway inhibitor (abiraterone, apalutamide, or enzalutamide) in oncology clinics. Participants will be consecutively enrolled at Ankara Etlik City Hospital and Gazi University Hospital.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically or cytologically confirmed metastatic hormone-sensitive prostate cancer (mHSPC) * Planned initiation of androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (abiraterone, apalutamide, or enzalutamide) as part of routine clinical care * Ability to complete patient-reported outcome questionnaires (FACT-Cog, FACT-F, PHQ-9, PSQI) * Written informed consent obtained Exclusion Criteria: * Prior systemic therapy for metastatic prostate cancer (except ≤3 months of ADT) * Known history of severe cognitive impairment that precludes completion of questionnaires * Concurrent active malignancy requiring systemic treatment * Inability to comply with study procedures or follow-up * Any condition judged by the investigator to compromise participation or data integrity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic hormone-sensitive prostate cancer (MHSPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression Fatigue insomnia metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic hormone-sensitive prostate cancer (MHSPC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Etlik City Hospital Medical Oncology Department

    RECRUITING

    Ankara, Yenimahalle, 06270, Turkey (Türkiye)

  • Gazi University Medical Oncology Department

    RECRUITING

    Ankara, Çankaya, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.